Streptomycin
- PDF / 169,653 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 135 Views
1 S
Bilateral sensorineural hearing loss: case report A 44-year-old man developed bilateral sensorineural hearing loss following treatment with streptomycin for multi-drug-resistant tuberculosis (TB). The man was hospitalised for management of the multi-drug-resistant tuberculosis (rifampicin-resistant tuberculosis; MDR/RRTB). He had completed the first-line of therapy, comprising isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E), followed by 4 months of isoniazid and rifampicin (2RHZE/4RH). Due to persistence of symptoms, he was retreated with an 8-month regimen, involving streptomycin [S; route and dosage not stated] for the first 2 months (2SRHZE/1RHZE/5RHE). However, he subsequently developed bilateral sensorineural hearing loss as a manifestation of streptomycin-induced ototoxicity [time to reaction onset not stated]. MDR/RR-TB was suspected due to the persistence of symptoms after his second rifampicin-susceptible TB (RS-TB) therapy. Subsequent investigations following his current admission suggested a complicated pulmonary tuberculosis, while audiometry tests confirmed bilateral sensorineural hearing loss (105 and 103dB on the left and right, respectively), which was attributed to streptomycin ototoxicity. He eventually passed away during the third month of admission [ADR outcome and immediate cause of death not stated]. Katoto PDMC, et al. A miner with No left lung: Extensive pulmonary destruction in delayed effective Multi-Drug-Resistant Tuberculosis treatment. Respiratory Medicine 803517837 Case Reports 31: 2020. Available from: URL: http://doi.org/10.1016/j.rmcr.2020.101234
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
